Recent corporate announcements from Avacta Group highlight ongoing clinical trial developments for its proprietary drug conjugate pipeline, executive leadership transitions focused on accelerating its oncology therapeutic portfolio, and strategic capital allocation updates reported through London Stock Exchange regulatory filings.